Aprea strengthens its board
STOCKHOLM – July 21, 2015. Aprea AB, a Karolinska Development AB (STO: KDEV) portfolio company, announces that Bernd R. Seizinger has been elected as Executive Chairman and Jonathan Hepple a new member of the board.
Bernd R. Seizinger, M.D., Ph.D., is Chairman of Opsona Therapeutics Ltd. He was formerly Vice President, Oncology Drug Discovery at Bristol-Myers Squibb, Director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital and Associate Professor at Harvard Medical School in Boston, MA, USA, as well as President & CEO of oncology drug discovery and clinical development company GPC Biotech (U.S. and Germany). Dr. Seizinger has authored more than 100 publications and has been the recipient of numerous scientific awards. He has been on the board of a number of private and public biotech and pharma companies in the U.S. and Europe.
Jonathan Hepple PhD., represents Rosetta Capital Ltd where he is one of the founding Partners. Jonathan has over 17 years of investment experience in the life sciences initially at Rothschild Asset Management and then as co-founder of BioScience Managers Ltd. Jonathan currently serves as a Director on the Board of a number of private life science companies including Novimmune, Procertus and Clanotech. He was previously a Director of Covagen AG and Opsona Therapeutics. He received his PhD from Cambridge University for cancer research.
“Jonathan’s experience in the life science industry, as well as his unique network in the international pharmaceutical and financial industry, and Bernd with his extensive senior leadership experience from the pharmaceutical and biotechnology industries will be a great benefit to the company as we move forward.”, says Ulf Björklund, CEO.
For further information, please contact:
Ulf Björklund, CEO, Aprea AB
Phone: +46 (0) 8 508 845 04, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Aprea AB
Aprea AB is a Swedish biotech company focusing on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. The main owner of Aprea is KDev Investments AB, part of Karolinska Development AB (publ). The other main owners are Östersjöstiftelsen, Praktikerinvest and KCIF Co-Investment Fund KB. For more information, please visit www.aprea.com
APR-246 has been developed based on results from researchers at Karolinska Institutet, and has been shown to reactivate non-functional tumor suppressor protein p53 and induce programmed cell death in many human cancer cells. Preclinical studies have confirmed that APR-246 can activate mutated p53 and demonstrated single agent efficacy and very strong synergy with conventional anti-cancer agents in vitro and in vivo. A clinical Phase Ib/II study in hematological malignancies and prostate cancer has been completed, demonstrating a favorable safety profile and both biological and clinical responses. A Phase Ib/II proof-of-concept study in ovarian cancer patients carrying mutant p53 is currently ongoing.
About the Phase Ib/II PiSARRO trial
The Phase Ib/II trial is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of APR-246 in combination with carboplatin (AUC 5) and pegylated doxorubicin (30 mg/m2), a second line standard of care chemotherapy for relapsed platinum sensitive high grade serous ovarian cancer. The Phase Ib/II trial is a two-part study that will enroll approximately 180 patients. Part A is an open-label, multiple ascending dose study. The primary objectives of Phase Ib are to evaluate the safety and tolerability of APR-246 in combination with carboplatin and pegylated doxorubicin, and to confirm the dose of APR-246. Pending successful completion of this phase, Aprea expects to initiate Part B of the trial, which will be a randomized, controlled study investigating the safety and antitumor activity of APR-246 administered in combination with carboplatin and pegylated doxorubicin, compared with carboplatin and pegylated doxorubicin alone. Primary end point of Phase II will be Progression Free Survival (PFS). For details on the PiSARRO trial please visit: www.ClinicalTrials.gov.